CJC-1295 Peptide | MendStride

Peptide Therapy

CJC-1295 without DAC is a modified GHRH analogue studied for prolonged endogenous GH and IGF-1 signalling in research settings.

C152H252N44O42

Modified GHRH Analogue

Studied for GH/IGF-1 Release

Research Only

Result Duration

Typically 3 months

Price From

£350 / month

At A Glance

Research Only

Result Duration

Typically 3 months

Price From

£350 / month

What Is CJC-1295 noDAC?

CJC-1295 without DAC, often grouped with modified GRF analogues, is a synthetic growth hormone-releasing hormone analogue designed to resist rapid degradation.

Human research has mainly examined pharmacokinetics, GH responses, IGF-1 responses and tolerability rather than long-term clinical endpoints.

Research Snapshot & Compound Overview

Human CJC-1295 data focus mainly on endocrine signalling, pharmacokinetics and short-term tolerability.

The best-known human study assessed how CJC-1295 altered growth hormone and IGF-1 secretion in healthy adults across two placebo-controlled trials. Published work does not establish broad long-term clinical benefits beyond those endocrine measurements.

CJC-1295 without DAC is a synthetic GHRH analogue engineered to be more stable than native GHRH.

Type: Synthetic peptide analogue Structure: Long-acting GHRH analogue Class: Growth hormone secretagogue / GHRH receptor agonist

CJC-1295 without DAC binds the GHRH receptor and stimulates pulsatile release of endogenous growth hormone, with downstream effects on IGF-1.

The noDAC form has a shorter residence time than DAC-linked CJC-1295 but is still more stable than native GHRH.

How Does CJC1295 noDAC Work?

CJC-1295 without DAC binds the GHRH receptor and stimulates pulsatile release of endogenous growth hormone, with downstream effects on IGF-1.

The noDAC form has a shorter residence time than DAC-linked CJC-1295 but is still more stable than native GHRH.

How Does CJC1295 noDAC Work?

What our clients say about us

This is an excellent clinic. I attended with a concern about my brain and was gives a stack of peptides. My cognition has improved a lot! All of the staff are professional, friendly and they will genuinely put you at ease. The doctor I saw was extremely knowledgeable and understanding. He listened carefully, and worked collaboratively with me to agree on a peptide stack.

Shah

FAQs

Answers to common questions.

CJC-1295 without DAC, often grouped with modified GRF analogues, is a synthetic growth hormone-releasing hormone analogue designed to resist rapid degradation.

Human research has mainly examined pharmacokinetics, GH responses, IGF-1 responses and tolerability rather than long-term clinical endpoints.

The evidence base includes controlled human endocrine studies, but long-term outcome data remain limited.

CJC-1295 without DAC binds the GHRH receptor and stimulates pulsatile release of endogenous growth hormone, with downstream effects on IGF-1.

The noDAC form has a shorter residence time than DAC-linked CJC-1295 but is still more stable than native GHRH.

Yes. Short-term placebo-controlled human studies have been published.

Current interest centres on pulsatile GH release rather than direct hormone replacement.

It is not native human GHRH; it is a modified analogue designed to act on the same receptor pathway.

This page is marked research only because mechanistic and endocrine data do not automatically translate into proven broad clinical benefit.

Research Overview

Consultation

A free phone call, video or in person consultation.

Treatment

Once you’ve spoken with your medical professional you’ll be given a treatment plan.

Aftercare

Your doses will be shipped or given to you to be used during the treatment plan period.

Related Peptides

C38H49N9O5

Selective ghrelin agonist

Studied for GH & motility

Ipamorelin Peptide

C78H123N23O23S2

hGH(176-191) fragment

Lipolysis research peptide

AOD9604 Peptide

C221H366N72O67S

Synthetic GHRH analogue

Initial US approval: 2010

Tesamorelin

C38H49N9O5

Selective ghrelin agonist

Studied for GH & motility

Ipamorelin Peptide

C78H123N23O23S2

hGH(176-191) fragment

Lipolysis research peptide

AOD9604 Peptide

C221H366N72O67S

Synthetic GHRH analogue

Initial US approval: 2010

Tesamorelin

PRICING

Transparent pricing with a structured plan tailored to your treatment goals and clinical needs.

NAD+ IV Infusion 750mg